Myoblasts are defined as stem cells containing skeletal muscle cell precursors. A decade of experimental work has revealed many properties of myoblasts, including the stability of resulting hybrid myofibers without immune suppression, the persistence of transgene expression, and the lack of tumorigenicity. Early phase clinical trials also showed that myoblast-based therapy is a promising approach for many intractable clinical conditions, including both muscle-related and non-muscle-related diseases. The potential application of myoblast therapy may be in the treatment of genetic muscle diseases, cardiomyocyte damaged heart diseases, and urinary incontinence. This review will provide an overview of myoblast biology, along with discussion of the potential application in clinical medicine. In addition, problems in current myoblast therapy and possible future improvements will be addressed.
AlessandriG.; PaganoS.; BezA.; BenettiA.; PozziS.; IannoloG.; BaronioM.; InverniciG.; CarusoA.; MunerettoC.; BisleriG.; ParatiE.Isolation and culture of human muscle-derived stem cells able to differentiate into myogenic and neurogenic cell lineages.Lancet364: 1872–1883; 2004.
2.
AzarnoushK.; MaurelA.; SebbahL.; CarrionC.; BisseryA.; MandetC.; PoulyJ.; BrunevalP.; HagegeA. A.; MenascheP.Enhancement of the functional benefits of skeletal myoblast transplantation by means of coad-ministration of hypoxia-inducible factor 1alpha.J. Thorac. Cardiovasc. Surg.130: 173–179; 2005.
3.
BakerR. S.; BonnerP. H.; PorterJ. D.; MadhatM. N.; GrossJ.Myoblast transfer therapy in the treatment of ptosis: A preliminary study.J. Pediatr. Ophthalmol. Strabismus30: 113–117; 1993.
4.
BaroffioA.; HamannM.; BernheimL.; Bochaton-PiallatM. L.; GabbianiG.; BaderC. R.Identification of self-renewing myoblasts in the progeny of single human muscle satellite cells.Differentiation60: 47–57; 1996.
5.
BeauchampJ. R.; MorganJ. E.; PagelC. N.; PartridgeT. A.Dynamics of myoblast transplantation reveal a discrete minority of precursors with stem cell-like properties as the myogenic source.J. Cell Biol.144: 1113–1122; 1999.
6.
Belles-IslesM.; RoyR.; DansereauG.; GouletM.; RoyB.; BouchardJ. P.; TremblayJ. P.Rapid selection of donor myoblast clones for muscular dystrophy therapy using cell surface expression of NCAM.Eur. J. Histochem.37: 375–380; 1993.
7.
BenabdallahB. F.; BouchentoufM.; TremblayJ. P.Improved success of myoblast transplantation in mdx mice by blocking the myostatin signal.Transplantation79: 1696–1702; 2005.
8.
BouchentoufM.; BenabdallahB. F.; TremblayJ. P.Myoblast survival enhancement and transplantation success improvement by heat-shock treatment in mdx mice.Transplantation77: 1349–1356; 2004.
9.
BrasseletC.; MorichettiM. C.; MessasE.; CarrionC.; BisseryA.; BrunevalP.; VilquinJ. T.; LafontA.; HagegeA. A.; MenascheP.; DesnosM.Skeletal myoblast transplantation through a catheter-based coronary sinus approach: An effective means of improving function of infarcted myocardium.Eur. Heart J.26: 1551–1556; 2005.
10.
ChancellorM. B.; YokoyamaT.; TirneyS.; MattesC. E.; OzawaH.; YoshimuraN.; de GroatW. C.; HuardJ.Preliminary results of myoblast injection into the urethra and bladder wall: A possible method for the treatment of stress urinary incontinence and impaired detrusor contractility.Neurourol. Urodyn.19: 279–287; 2000.
11.
CollinsC. A.; OlsenI.; ZammitP. S.; HeslopL.; PetrieA.; PartridgeT. A.; MorganJ. E.Stem cell function, self-renewal, and behavioral heterogeneity of cells from the adult muscle satellite cell niche.Cell122: 289–301; 2005.
12.
CooperR. N.; IrintchevA.; Di SantoJ. P.; ZweyerM.; MorganJ. E.; PartridgeT. A.; Butler-BrowneG. S.; MoulyV.; WernigA.A new immunodeficient mouse model for human myoblast transplantation.Hum. Gene Ther.12: 823–831; 2001.
13.
CooperR. N.; ThiessonD.; FurlingD.; Di SantoJ. P.; Butler-BrowneG. S.; MoulyV.Extended amplification in vitro and replicative senescence: key factors implicated in the success of human myoblast transplantation.Hum. Gene Ther.14: 1169–1179; 2003.
14.
DahlerA.; WadeR. P.; MuscatG. E.; WatersM. J.Expression vectors encoding human growth hormone (hGH) controlled by human muscle-specific promoters: prospects for regulated production of hGH delivered by myoblast transfer or intravenous injection.Gene145: 305–310; 1994.
15.
DayC. S.; KasemkijwattanaC.; MenetreyJ.; FloydS. S.Jr.; BoothD.; MorelandM. S.; FuF. H.; HuardJ.Myoblast-mediated gene transfer to the joint.J. Orthop. Res.15: 894–903; 1997.
16.
DibN.; McCarthyP.; CampbellA.; YeagerM.; PaganiF. D.; WrightS.; MacLellanW. R.; FonarowG.; EisenH. J.; MichlerR. E.; BinkleyP.; BucheleD.; KornR.; GhazoulM.; DinsmoreJ.; OpieS. R.; DiethrichE.Feasibility and safety of autologous myoblast transplantation in patients with ischemic cardiomyopathy.Cell Transplant.14: 11–19; 2005.
GueretteB.; SkukD.; CelestinF.; HuardC.; TardifF.; AsselinI.; RoyB.; GouletM.; RoyR.; EntmanM.; TremblayJ. P.Prevention by anti-LFA-1 of acute myoblast death following transplantation.J. Immunol.159: 2522–2531; 1997.
21.
HagegeA. A.; CarrionC.; MenascheP.; VilquinJ. T.; DubocD.; MarolleauJ. P.; DesnosM.; BrunevalP.Viability and differentiation of autologous skeletal myoblast grafts in ischaemic cardiomyopathy.Lancet361: 491–492; 2003.
22.
HamamoriY.; SamalB.; TianJ.; KedesL.Myoblast transfer of human erythropoietin gene in a mouse model of renal failure.J. Clin. Invest.95: 1808–1813; 1995.
23.
IrintchevA.; ZweyerM.; WernigA.Cellular and molecular reactions in mouse muscles after myoblast implantation.J. Neurocytol.24: 319–331; 1995.
24.
LaflammeM. A.; MurryC. E.Regenerating the heart.Nat. Biotechnol.23: 845–856; 2005.
25.
LawP. K.; BertoriniT. E.; GoodwinT. G.; ChenM.; FangQ. W.; LiH. J.; KirbyD. S.; FlorendoJ. A.; HerrodH. G.; GoldenG. S.Dystrophin production induced by myoblast transfer therapy in Duchenne muscular dystrophy.Lancet336: 114–115; 1990.
26.
LawP. K.; GoodwinT. G.; FangQ.; DuggiralaV.; LarkinC.; FlorendoJ. A.; KirbyD. S.; DeeringM. B.; LiH. J.; ChenM.Feasibility, safety, and efficacy of myoblast transfer therapy on Duchenne muscular dystrophy boys.Cell Transplant.1: 235–244; 1992.
27.
LawP. K.; GoodwinT. G.; FangQ.; HallT. L.; QuinleyT.; VastaghG.; DuggiralaV.; LarkinC.; FlorendoJ. A.; LiL.; JacksonT.; YooT. J.; ChaseN.; NeelM.; KrahnT.; HolcombR.First human myoblast transfer therapy continues to show dystrophin after 6 years.Cell Transplant.6: 95–100; 1997.
MendellJ. R.; KisselJ. T.; AmatoA. A.; KingW.; SignoreL.; PriorT. W.; SahenkZ.; BensonS.; McAndrewP. E.; RiceR.Myoblast transfer in the treatment of Duchenne's muscular dystrophy.N. Engl. J. Med.333: 832–838; 1995.
37.
MillerR. G.; SharmaK. R.; PavlathG. K.; GussoniE.; MynhierM.; LanctotA. M.; GrecoC. M.; SteinmanL.; BlauH. M.Myoblast implantation in Duchenne muscular dystrophy: The San Francisco study.Muscle Nerve20: 469–478; 1997.
38.
NeumeyerA. M.; CrosD.; McKenna-YasekD.; ZawadzkaA.; HoffmanE. P.; PegoraroE.; HunterR. G.; MunsatT. L.; BrownR. H.Jr.Pilot study of myoblast transfer in the treatment of Becker muscular dystrophy.Neurology51: 589–592; 1998.
39.
OttH. C.; KroessR.; BonarosN.; MarksteinerR.; MargreiterE.; SchachnerT.; LauferG.; HeringS.Intramyocardial microdepot injection increases the efficacy of skeletal myoblast transplantation.Eur. J. Cardiothorac. Surg.27: 1017–1021; 2005.
40.
OzawaC. R.; SpringerM. L.; BlauH. M.A novel means of drug delivery: myoblast-mediated gene therapy and regulatable retroviral vectors.Annu. Rev. Pharmacol. Toxicol.40: 295–317; 2000.
41.
PoulyJ.; HagegeA. A.; VilquinJ. T.; BisseryA.; RoucheA.; BrunevalP.; DubocD.; DesnosM.; FiszmanM.; FromesY.; MenascheP.Does the functional efficacy of skeletal myoblast transplantation extend to nonischemic cardiomyopathy?Circulation110: 1626–1631; 2004.
42.
PouzetB.; GhostineS.; VilquinJ. T.; GarcinI.; ScorsinM.; HagegeA. A.; DubocD.; SchwartzK.; MenascheP.Is skeletal myoblast transplantation clinically relevant in the era of angiotensin-converting enzyme inhibitors?Circulation104: I223–228; 2001.
QuZ.; BalkirL.; van DeutekomJ. C.; RobbinsP. D.; PruchnicR.; HuardJ.Development of approaches to improve cell survival in myoblast transfer therapy.J. Cell Biol.142: 1257–1267; 1998.
45.
RandoT. A.; BlauH. M.Primary mouse myoblast purification, characterization, and transplantation for cell-mediated gene therapy.J. Cell Biol.125: 1275–1287; 1994.
46.
RomanM.; AxelrodJ. H.; DaiY.; NaviauxR. K.; FriedmannT.; VermaI. M.Circulating human or canine factor IX from retrovirally transduced primary myoblasts and established myoblast cell lines grafted into murine skeletal muscle.Somat. Cell. Mol. Genet.18: 247–258; 1992.
47.
SchneiderB. L.; PedutoG.; AebischerP.A self-immunomodulating myoblast cell line for erythropoietin delivery.Gene Ther.8: 58–66; 2001.
48.
SiminiakT.; KalawskiR.; FiszerD.; JerzykowskaO.; RzezniczakJ.; RozwadowskaN.; KurpiszM.Autologous skeletal myoblast transplantation for the treatment of postinfarction myocardial injury: Phase I clinical study with 12 months of follow-up.Am. Heart J.148: 531–537; 2004.
49.
SimonsonG. D.; GroskreutzD. J.; GormanC. M.; MacDonaldM. J.Synthesis and processing of genetically modified human proinsulin by rat myoblast primary cultures.Hum. Gene Ther.7: 71–78; 1996.
50.
SmytheG. M.; HodgettsS. I.; GroundsM. D.Problems and solutions in myoblast transfer therapy.J. Cell. Mol. Med.5: 33–47; 2001.
51.
SteendijkP.; SmitsP. C.; ValgimigliM.; van der GiessenW. J.; OnderwaterE. E.; SerruysP. W.Intramyocardial injection of skeletal myoblasts: Long-term follow-up with pressure-volume loops.Nat. Clin. Pract. Cardiovasc. Med.3(Suppl. 1): S94–S100; 2006.
52.
StewartJ. D.; MasiT. L.; CummingA. E.; MolnarG. M.; WentworthB. M.; SampathK.; McPhersonJ. M.; YaegerP. C.Characterization of proliferating human skeletal muscle-derived cells in vitro: Differential modulation of myoblast markers by TGF-beta2.J. Cell. Physiol.196: 70–78; 2003.
53.
TambaraK.; PremaratneG. U.; SakaguchiG.; KanemitsuN.; LinX.; NakajimaH.; SakakibaraY.; KimuraY.; YamamotoM.; TabataY.; IkedaT.; KomedaM.Administration of control-released hepatocyte growth factor enhances the efficacy of skeletal myoblast transplantation in rat infarcted hearts by greatly increasing both quantity and quality of the graft.Circulation112: I129–134; 2005.
TirneyS.; MattesC. E.; YoshimuraN.; YokayamaT.; OzawaH.; TzengE.; BirderL. A.; KanaiA. J.; HuardJ.; de GroatW. C.; ChancellorM. B.Nitric oxide synthase gene therapy for erectile dysfunction: comparison of plasmid, adenovirus, and adenovirus-transduced myoblast vectors.Mol. Urol.5: 37–43; 2001.
56.
TorrenteY.; D'AngeloM. G.; Del BoR.; DeLisoA.; CasatiR.; BentiR.; CortiS.; ComiG. P.; GerundiniP.; AnichiniA.; ScarlatoG.; BresolinN.Extracorporeal circulation as a new experimental pathway for myoblast implantation in mdx mice.Cell Transplant.8: 247–258; 1999.
TremblayJ. P.; MalouinF.; RoyR.; HuardJ.; BouchardJ. P.; SatohA.; RichardsC. L.Results of a triple blind clinical study of myoblast transplantations without immunosuppressive treatment in young boys with Duchenne muscular dystrophy.Cell Transplant.2: 99–112; 1993.
59.
UrishK.; KandaY.; HuardJ.Initial failure in myoblast transplantation therapy has led the way toward the isolation of muscle stem cells: Potential for tissue regeneration.Curr. Top. Dev. Biol.68: 263–280; 2005.
60.
van den BosE. J.; ThompsonR. B.; WagnerA.; MahrholdtH.; MorimotoY.; ThomsonL. E.; WangL. H.; DunckerD. J.; JuddR. M.; TaylorD. A.Functional assessment of myoblast transplantation for cardiac repair with magnetic resonance imaging.Eur. J. Heart Fail.7: 435–443; 2005.
61.
von DegenfeldG.; BanfiA.; SpringerM. L.; BlauH. M.Myoblast-mediated gene transfer for therapeutic angiogenesis and arteriogenesis.Br. J. Pharmacol.140: 620–626; 2003.
62.
WalshF. S.N-CAM is a target cell surface antigen for the purification of muscle cells for myoblast transfer therapy.Adv. Exp. Med. Biol.280: 41–46; 1990.
63.
WhiteJ. D.; BowerJ. J.; KurekJ. B.; AustinL.Leukemia inhibitory factor enhances regeneration in skeletal muscles after myoblast transplantation.Muscle Nerve24: 695–697; 2001.
64.
YaoS. N.; SmithK. J.; KurachiK.Primary myoblast-mediated gene transfer: Persistent expression of human factor IX in mice.Gene Ther.1: 99–107; 1994.
65.
YoshidaN.; YoshidaS.; KoishiK.; MasudaK.; NabeshimaY.Cell heterogeneity upon myogenic differentiation: Down-regulation of MyoD and Myf-5 generates ‘reserve cells’.J. Cell. Sci.111(Pt. 6): 769–779; 1998.
